The most commonly reported PT-141 side effects in clinical trials were nausea, flushing, headache and injection site reactions, alongside a transient rise in blood pressure. Here is what the published safety data actually shows about compounded PT-141, reported honestly.
PT-141 is the research name for bremelanotide, a melanocortin receptor agonist acting at MC3R and MC4R in the hypothalamus. Because it works centrally rather than on blood flow, its side effect profile looks nothing like a PDE5 inhibitor's. See our guide to how bremelanotide works.
The figures below come from the phase 3 RECONNECT programme, two randomized double-blind placebo-controlled trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), and from the labeling for Vyleesi, the 1.75 mg subcutaneous autoinjector approved in 2019.
What the Trials Recorded, Side by Side
These are pooled adverse reactions at the 1.75 mg subcutaneous dose. Placebo rates sit alongside them because they are the honest reference point.
| Adverse reaction | Bremelanotide 1.75 mg | Placebo |
|---|---|---|
| Nausea | 40.0% | 1.3% |
| Flushing | 20.3% | 0.3% |
| Injection site reactions | 13.2% | 8.4% |
| Headache | 11.3% | 1.9% |
| Vomiting | 4.8% | 0.2% |
| Cough | 3.3% | 1.3% |
| Fatigue | 3.2% | 0.5% |
| Hot flush | 2.7% | 0.2% |
Nausea dominates the profile. Injection site reactions also occurred at meaningful rates on placebo, worth remembering before reading any single figure alone.
Nausea Is the Effect Most People Notice
Nausea was reported by 40 percent of participants receiving bremelanotide, against 1.3 percent on placebo. It is the defining bremelanotide side effect and the one most likely to decide whether someone continues.
The approved labeling records that 13 percent required anti-emetic therapy and 8 percent discontinued the trials because of nausea. It also notes that nausea improved for most participants with the second dose.
Most events were mild to moderate and settled within hours. That is not the same as trivial: roughly one in twelve participants stopped entirely.
Flushing, Headache and Injection Site Reactions
Flushing was reported in 20.3 percent of treated participants versus 0.3 percent on placebo, consistent with melanocortin receptor activity. Headache followed at 11.3 percent versus 1.9 percent.
Injection site reactions appeared in 13.2 percent of treated participants, but placebo produced them in 8.4 percent, so much of that belongs to injecting rather than to the molecule. Across the clinical development programme these reactions were characterised as mostly mild to moderate.
Vomiting, cough, fatigue and hot flush each fell in the 2 to 5 percent range: low-severity effects rather than danger signals.
Blood Pressure and Heart Rate: The Finding That Shapes Everything Else
This is the finding that determines who can be considered a candidate at all. Bremelanotide produces a transient increase in blood pressure with a modest decrease in heart rate after each dose.
The labeling describes maximal mean increases of about 6 mmHg systolic and 3 mmHg diastolic, with heart rate reductions up to 5 bpm. The effect peaks 2 to 4 hours after injection and usually resolves within 12 hours.
An ambulatory blood pressure study in 397 premenopausal women found peak systolic increases of 3.1 to 3.2 mmHg at 1.75 mg during the first four hours, heart rate falling 4.6 to 4.7 bpm, and most elevations lasting 15 minutes or less.
Route mattered in development. An intranasal formulation was studied earlier and was not advanced to FDA approval because of blood pressure findings tied to that route, a history covered in our nasal spray versus injection comparison.
Focal Hyperpigmentation With Repeated Dosing
Bremelanotide belongs to the melanocortin peptide family, so it also interacts with MC1R, the receptor involved in pigmentation. The documented result is focal hyperpigmentation on the face, gums and breasts.
The labeling reports this in about 1 percent of participants dosed up to eight times per month, with higher rates among participants with darker skin. Under daily dosing for eight consecutive days, 38 percent developed hyperpigmentation.
Resolution after stopping was not confirmed in every affected participant. It may not always reverse. The effect scales with dosing frequency, one reason the label caps monthly use at eight doses. PT-141 is related to the melanotan research lineage but is not a tanning product.
Who Was Excluded From the Trials
Trial populations define what safety data can tell you. RECONNECT enrolled premenopausal women with acquired, generalized HSDD and excluded people with uncontrolled hypertension or known cardiovascular disease. The published RECONNECT analysis reflects that population, not the general public.
Vyleesi is contraindicated in uncontrolled hypertension and established cardiovascular disease, and is not recommended for people at high cardiovascular risk. Severe hepatic impairment can increase both the incidence and severity of nausea and vomiting.
The approval covers premenopausal women only. Use in men is off-label, and phase 2 work in men with erectile dysfunction showed a dose-dependent erectile response in roughly the 30 to 60 minute range. See our reviews for women and men.
Side effects are a conversation to have with a clinician, not something to guess at. A licensed provider reviews your blood pressure history, cardiovascular risk and current medications before PT-141 is considered.
See PT-141 at Telos RxIs PT-141 Safe? Reading the Evidence Honestly
The fair summary: in the studied population, bremelanotide had a tolerability problem more than a danger problem. Effects were frequent, mostly mild to moderate, mostly short-lived, and the FDA judged the profile acceptable enough to approve in 2019.
The genuine concerns sit in three places. The cardiovascular effect is real, which is why uncontrolled hypertension and known cardiovascular disease are contraindications rather than cautions. Hyperpigmentation may not fully reverse. And the picture beyond the trial windows is not well characterised.
What to Tell Your Provider
These items map directly onto the documented risks, and a provider needs them before PT-141 can be considered.
- Blood pressure history, including any hypertension diagnosis and how well controlled it currently is.
- Any cardiovascular disease, prior cardiac events, or a significant risk-factor picture.
- Every current medication, especially blood pressure medications and anything affecting heart rate.
- Liver conditions, given the effect of severe hepatic impairment on nausea and vomiting.
- Pregnancy status or plans, and whether you are premenopausal or postmenopausal.
- Any history of pigmentation changes or skin conditions, along with your skin tone.
- What you have already tried, including PDE5 inhibitors. Our PT-141 versus Viagra and Cialis comparison explains why the two categories place risk in different places.
How Compounded PT-141 Differs From the Studied Product
The figures above describe an FDA-approved 1.75 mg subcutaneous autoinjector studied in a defined population. Compounded PT-141 is different: prepared by licensed US compounding pharmacies under federal compounding regulations, not FDA-approved, and not the subject of its own trial programme.
That does not make the trial data irrelevant. Same molecule, same receptor activity driving nausea, flushing and blood pressure change. It does mean the branded product's numbers are not a guarantee of an identical profile. See our PT-141 dosage guide and our review of research-backed benefits.
At Telos Rx, PT-141 is an as-needed subcutaneous dose taken ahead of anticipated intimacy, subject to medical approval by a licensed provider. Evaluation is asynchronous through an online intake, available in all 50 states, and formulations may vary by state.
Frequently Asked Questions
What are the most common PT-141 side effects?
In placebo-controlled phase 3 trials, nausea was most common at 40 percent, followed by flushing at 20.3 percent, injection site reactions at 13.2 percent and headache at 11.3 percent. Vomiting, cough, fatigue and hot flush each fell in the 2 to 5 percent range.
How long do PT-141 side effects last?
Most reported effects were short-lived. Nausea generally settled within hours, and the labeling notes it improved for most participants by the second dose. The transient blood pressure increase and heart rate decrease peaked around 2 to 4 hours after injection and usually resolved within 12 hours.
Is PT-141 safe for people with high blood pressure?
Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease, and those groups were excluded from the trials. It is also not recommended for people at high cardiovascular risk. Anyone with a blood pressure history needs a full review by a licensed provider before PT-141 is considered.
Does PT-141 cause skin darkening?
Focal hyperpigmentation has been reported with repeated dosing, affecting the face, gums and breasts in about 1 percent of participants dosed up to eight times monthly, and 38 percent under daily dosing for eight days. Rates were higher in people with darker skin, and resolution was not confirmed in every case.
Are bremelanotide side effects different in men?
The detailed safety tables come from trials in premenopausal women, since that is the approved population. Use in men is off-label and the phase 2 male data set is smaller. The underlying receptor activity is the same, so nausea, flushing and the blood pressure effect remain the relevant concerns.
How do PT-141 peptide side effects compare with Viagra?
They differ because the mechanisms differ. PDE5 inhibitors act on blood vessels and can lower blood pressure, which is why nitrates are contraindicated. Bremelanotide acts centrally and transiently raises blood pressure instead. Neither profile is inherently milder; they simply place risk in different places.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
If you want this safety picture reviewed against your own health history, see compounded PT-141 at Telos Rx, then start a private online evaluation: men start here or women start here. Every request is reviewed asynchronously by a licensed provider, and approval is not guaranteed.